Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Green tea extract (GTE) is a botanical extract derived from the leaves of *Camellia sinensis*, primarily characterized by its high concentration of polyphenolic catechins, most notably (-)-epigallocatechin-3-gallate (EGCG). GTE is widely utilized as a dietary supplement and investigated as a therapeutic agent for obesity, metabolic syndrome, and cardiovascular health. Its mechanism of action involves the inhibition of catechol-O-methyltransferase (COMT), which leads to increased levels of norepinephrine and subsequent stimulation of thermogenesis and fat oxidation. Additionally, GTE has been shown to activate the AMP-activated protein kinase (AMPK) pathway, reduce intestinal lipid absorption, and modulate obesity-related hormones such as adiponectin, ghrelin, and leptin. Clinical studies have demonstrated its potential to reduce body weight, body mass index (BMI), waist circumference, and low-density lipoprotein cholesterol (LDL-C), particularly when combined with endurance training or dietary modifications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on green tea extract.